Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study

Renáta Kószó, Dóra Sántha, László Büdi, József Erfán, Károly Győrfy, Z. Horváth, Judit Kocsis, László Landherr, Erika Hitre, Károly Máhr, Gábor Pajkos, Zsuzsanna Pápai, Zsuzsanna Kahán

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Due to the limited experience with capecitabine plus docetaxel (XT) combination in the first-line treatment of metastatic breast cancer in Hungary, the main objective of the study was to analyze the effectiveness and tolerability of XT therapy. A prospective, open-label, non-randomized, single-arm, multicenter, observational study was designed. All female patients were eligible whose metastatic breast cancer could be treated with the XT protocol according to the summary of product characteristics of the drugs. The median progression free survival was 9.9 ± 3.0 months. Time to treatment failure was 4.6 ± 5.1 months on average. The overall response rate was 28.9 %, the clinical benefit rate was 73.3 %. The treatment was discontinued in 35.6 % of patients due to disease progression and in 20.0 % due to adverse events (AE). 33 patients with a total of 73 AEs have been reported, and 13 of them had serious adverse events (SAE). The efficacy and the safety profile of XT chemotherapy proven in the study are consistent with the results demonstrated in randomized trials. First-line XT chemotherapy effectively improves the PFS in metastatic breast cancer.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalPathology and Oncology Research
DOIs
Publication statusAccepted/In press - Oct 22 2016

Fingerprint

docetaxel
Observational Studies
Breast Neoplasms
Drug Therapy
Hungary
Treatment Failure
Multicenter Studies
Disease-Free Survival
Disease Progression
Therapeutics
Safety
Pharmaceutical Preparations
Capecitabine

Keywords

  • Capecitabine
  • Docetaxel
  • HER2-negative metastatic breast cancer
  • Toxicity

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Cite this

Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer : an Observational Study. / Kószó, Renáta; Sántha, Dóra; Büdi, László; Erfán, József; Győrfy, Károly; Horváth, Z.; Kocsis, Judit; Landherr, László; Hitre, Erika; Máhr, Károly; Pajkos, Gábor; Pápai, Zsuzsanna; Kahán, Zsuzsanna.

In: Pathology and Oncology Research, 22.10.2016, p. 1-7.

Research output: Contribution to journalArticle

Kószó, R, Sántha, D, Büdi, L, Erfán, J, Győrfy, K, Horváth, Z, Kocsis, J, Landherr, L, Hitre, E, Máhr, K, Pajkos, G, Pápai, Z & Kahán, Z 2016, 'Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study', Pathology and Oncology Research, pp. 1-7. https://doi.org/10.1007/s12253-016-0129-7
Kószó, Renáta ; Sántha, Dóra ; Büdi, László ; Erfán, József ; Győrfy, Károly ; Horváth, Z. ; Kocsis, Judit ; Landherr, László ; Hitre, Erika ; Máhr, Károly ; Pajkos, Gábor ; Pápai, Zsuzsanna ; Kahán, Zsuzsanna. / Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer : an Observational Study. In: Pathology and Oncology Research. 2016 ; pp. 1-7.
@article{8c586d22531e4eaaab7d3df0a462c884,
title = "Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study",
abstract = "Due to the limited experience with capecitabine plus docetaxel (XT) combination in the first-line treatment of metastatic breast cancer in Hungary, the main objective of the study was to analyze the effectiveness and tolerability of XT therapy. A prospective, open-label, non-randomized, single-arm, multicenter, observational study was designed. All female patients were eligible whose metastatic breast cancer could be treated with the XT protocol according to the summary of product characteristics of the drugs. The median progression free survival was 9.9 ± 3.0 months. Time to treatment failure was 4.6 ± 5.1 months on average. The overall response rate was 28.9 {\%}, the clinical benefit rate was 73.3 {\%}. The treatment was discontinued in 35.6 {\%} of patients due to disease progression and in 20.0 {\%} due to adverse events (AE). 33 patients with a total of 73 AEs have been reported, and 13 of them had serious adverse events (SAE). The efficacy and the safety profile of XT chemotherapy proven in the study are consistent with the results demonstrated in randomized trials. First-line XT chemotherapy effectively improves the PFS in metastatic breast cancer.",
keywords = "Capecitabine, Docetaxel, HER2-negative metastatic breast cancer, Toxicity",
author = "Ren{\'a}ta K{\'o}sz{\'o} and D{\'o}ra S{\'a}ntha and L{\'a}szl{\'o} B{\"u}di and J{\'o}zsef Erf{\'a}n and K{\'a}roly Győrfy and Z. Horv{\'a}th and Judit Kocsis and L{\'a}szl{\'o} Landherr and Erika Hitre and K{\'a}roly M{\'a}hr and G{\'a}bor Pajkos and Zsuzsanna P{\'a}pai and Zsuzsanna Kah{\'a}n",
year = "2016",
month = "10",
day = "22",
doi = "10.1007/s12253-016-0129-7",
language = "English",
pages = "1--7",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer

T2 - an Observational Study

AU - Kószó, Renáta

AU - Sántha, Dóra

AU - Büdi, László

AU - Erfán, József

AU - Győrfy, Károly

AU - Horváth, Z.

AU - Kocsis, Judit

AU - Landherr, László

AU - Hitre, Erika

AU - Máhr, Károly

AU - Pajkos, Gábor

AU - Pápai, Zsuzsanna

AU - Kahán, Zsuzsanna

PY - 2016/10/22

Y1 - 2016/10/22

N2 - Due to the limited experience with capecitabine plus docetaxel (XT) combination in the first-line treatment of metastatic breast cancer in Hungary, the main objective of the study was to analyze the effectiveness and tolerability of XT therapy. A prospective, open-label, non-randomized, single-arm, multicenter, observational study was designed. All female patients were eligible whose metastatic breast cancer could be treated with the XT protocol according to the summary of product characteristics of the drugs. The median progression free survival was 9.9 ± 3.0 months. Time to treatment failure was 4.6 ± 5.1 months on average. The overall response rate was 28.9 %, the clinical benefit rate was 73.3 %. The treatment was discontinued in 35.6 % of patients due to disease progression and in 20.0 % due to adverse events (AE). 33 patients with a total of 73 AEs have been reported, and 13 of them had serious adverse events (SAE). The efficacy and the safety profile of XT chemotherapy proven in the study are consistent with the results demonstrated in randomized trials. First-line XT chemotherapy effectively improves the PFS in metastatic breast cancer.

AB - Due to the limited experience with capecitabine plus docetaxel (XT) combination in the first-line treatment of metastatic breast cancer in Hungary, the main objective of the study was to analyze the effectiveness and tolerability of XT therapy. A prospective, open-label, non-randomized, single-arm, multicenter, observational study was designed. All female patients were eligible whose metastatic breast cancer could be treated with the XT protocol according to the summary of product characteristics of the drugs. The median progression free survival was 9.9 ± 3.0 months. Time to treatment failure was 4.6 ± 5.1 months on average. The overall response rate was 28.9 %, the clinical benefit rate was 73.3 %. The treatment was discontinued in 35.6 % of patients due to disease progression and in 20.0 % due to adverse events (AE). 33 patients with a total of 73 AEs have been reported, and 13 of them had serious adverse events (SAE). The efficacy and the safety profile of XT chemotherapy proven in the study are consistent with the results demonstrated in randomized trials. First-line XT chemotherapy effectively improves the PFS in metastatic breast cancer.

KW - Capecitabine

KW - Docetaxel

KW - HER2-negative metastatic breast cancer

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84992047337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992047337&partnerID=8YFLogxK

U2 - 10.1007/s12253-016-0129-7

DO - 10.1007/s12253-016-0129-7

M3 - Article

C2 - 27771885

AN - SCOPUS:84992047337

SP - 1

EP - 7

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

ER -